These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 30378106)

  • 21. Targeting Tumor Microenvironment for Cancer Therapy.
    Roma-Rodrigues C; Mendes R; Baptista PV; Fernandes AR
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response.
    Noman MZ; Messai Y; Carré T; Akalay I; Méron M; Janji B; Hasmim M; Chouaib S
    Crit Rev Immunol; 2011; 31(5):357-77. PubMed ID: 22142164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
    Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y
    J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Translational Landscape of mTOR Signaling in Integrating Cues Between Cancer and Tumor Microenvironment.
    Bazzichetto C; Conciatori F; Falcone I; Ciuffreda L
    Adv Exp Med Biol; 2020; 1223():69-80. PubMed ID: 32030685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?
    Puré E; Lo A
    Cancer Immunol Res; 2016 Apr; 4(4):269-78. PubMed ID: 27036971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insights into the tumor-stromal-immune cell metabolism cross talk in ovarian cancer.
    Tang PW; Frisbie L; Hempel N; Coffman L
    Am J Physiol Cell Physiol; 2023 Sep; 325(3):C731-C749. PubMed ID: 37545409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The application of the fibroblast activation protein α-targeted immunotherapy strategy.
    Jiang GM; Xu W; Du J; Zhang KS; Zhang QG; Wang XW; Liu ZG; Liu SQ; Xie WY; Liu HF; Liu JS; Wu BP
    Oncotarget; 2016 May; 7(22):33472-82. PubMed ID: 26985769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interventions that induce modifications in the tumor microenvironment.
    Bernhard EJ
    Cancer Radiother; 2011 Aug; 15(5):376-82. PubMed ID: 21571567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolism within the tumor microenvironment and its implication on cancer progression: An ongoing therapeutic target.
    Ocaña MC; Martínez-Poveda B; Quesada AR; Medina MÁ
    Med Res Rev; 2019 Jan; 39(1):70-113. PubMed ID: 29785785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibroblasts in the Tumor Microenvironment: Shield or Spear?
    Alkasalias T; Moyano-Galceran L; Arsenian-Henriksson M; Lehti K
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29883428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic Targeting of MicroRNAs in the Tumor Microenvironment.
    Raue R; Frank AC; Syed SN; Brüne B
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microenvironmental regulation of therapeutic response in cancer.
    Klemm F; Joyce JA
    Trends Cell Biol; 2015 Apr; 25(4):198-213. PubMed ID: 25540894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment.
    Whiteside TL
    Semin Immunol; 2018 Feb; 35():69-79. PubMed ID: 29289420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.
    Pitt JM; Marabelle A; Eggermont A; Soria JC; Kroemer G; Zitvogel L
    Ann Oncol; 2016 Aug; 27(8):1482-92. PubMed ID: 27069014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy.
    Bai Y; Wang Y; Zhang X; Fu J; Xing X; Wang C; Gao L; Liu Y; Shi L
    Int J Pharm; 2019 Oct; 570():118636. PubMed ID: 31446027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor Hypoxia: A Key Determinant of Microenvironment Hostility and a Major Checkpoint during the Antitumor Response.
    Francis A; Venkatesh GH; Zaarour RF; Zeinelabdin NA; Nawafleh HH; Prasad P; Buart S; Terry S; Chouaib S
    Crit Rev Immunol; 2018; 38(6):505-524. PubMed ID: 31002604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The tumor microenvironment of lymphomas: Insights into the potential role and modes of actions of checkpoint inhibitors.
    Menter T; Tzankov A; Dirnhofer S
    Hematol Oncol; 2021 Feb; 39(1):3-10. PubMed ID: 33105031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer.
    Vennin C; Murphy KJ; Morton JP; Cox TR; Pajic M; Timpson P
    Gastroenterology; 2018 Mar; 154(4):820-838. PubMed ID: 29287624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Strategical consideration of the interaction between tumor microenvironment and tumor immunity].
    Fujiwara H
    Rinsho Ketsueki; 2018; 59(10):1895-1904. PubMed ID: 30305490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.